Ipamorelin, Somatopause and Aging Research

Ipamorelin is one of the most studied peptides in research on the aging growth hormone axis. Much of that interest ties to a concept called somatopause, the gradual decline in growth hormone output that accompanies aging. This article explains what somatopause is, how Ipamorelin fits into research on it, and why its selectivity makes it a favoured tool in that literature.

What is somatopause?

Somatopause is the name given to the age-related fall in activity of the growth hormone and IGF-1 axis. As people age, the pituitary releases growth hormone in smaller, less frequent pulses, and downstream IGF-1 levels tend to drift lower. The term deliberately parallels menopause and andropause: it describes a slow, systemic endocrine change rather than a single event. Somatopause is a major theme in aging research because the GH axis touches so many tissue and metabolic pathways.

Where Ipamorelin fits

Ipamorelin is a growth hormone secretagogue. It belongs to the growth hormone-releasing peptide (GHRP) family and acts as an agonist at the growth hormone secretagogue receptor (GHS-R), the same receptor targeted by the hormone ghrelin. In research models, agonising this receptor prompts the pituitary to release growth hormone in a pulse. That makes Ipamorelin a useful probe for studying how the GH axis responds when it is stimulated, which is directly relevant to somatopause research where the question is often how a quieter axis behaves under a secretagogue signal.

Why selectivity matters in aging models

Ipamorelin is frequently described as one of the more selective GHRPs. In research terms, it stimulates growth hormone release without strongly driving the release of other pituitary hormones such as cortisol and prolactin that some older secretagogues affect. For aging studies this cleanliness is valuable: it lets researchers isolate the growth hormone response from confounding hormonal noise. A selective tool produces data that is easier to interpret, which is a large part of why Ipamorelin appears so often in this literature.

The GH axis at a glance

Ipamorelin and CJC-1295 together

In research settings Ipamorelin is often studied alongside CJC-1295, a growth hormone-releasing hormone (GHRH) analogue. The two work on complementary steps of the axis: CJC-1295 acts on the GHRH pathway while Ipamorelin acts on the GHS-R pathway. Pairing a GHRH analogue with a GHS-R agonist is a common design in GH-axis research because the two signals converge on the same output. This is why the compounds are frequently offered and examined as a pair. For definitions of terms like agonist, secretagogue and analogue, see our peptide guide.

Why researchers favour a pulsatile approach

One reason Ipamorelin draws attention in aging research is that it works with the body’s own pulsatile pattern rather than flooding the system with a continuous signal. Growth hormone is naturally released in bursts, and a secretagogue that prompts a pulse keeps that rhythm intact in study models. Preserving pulsatility is often considered important because the timing and shape of GH release, not just the total amount, is part of what the axis responds to. This makes secretagogue-based tools like Ipamorelin a natural fit for studying an axis that has grown quieter with age, since they probe the system in its own language rather than overriding it.

Buy Ipamorelin research peptides in Canada

LYFE Science stocks CJC-1295 (No DAC) + Ipamorelin for Canadian researchers. We are a Canadian supplier shipping nationwide by Canada Post, with flat $25 shipping and free delivery on orders over $150. Orders paid before noon ET dispatch the same day and reach most of Canada in 1-3 business days, in neutral packaging. Every lot is checked by HPLC and mass spectrometry, with a COA available on request. We accept Interac e-Transfer and crypto (BTC, ETH, SOL, USDC, USDT).

Check current availability and pricing below.

Buy CJC-1295 + Ipamorelin in Canada